Skip to main content

Lupus

      #ACR23 Abstr#1479 In N=66 patients with #SLE, 29% had high risk HPV infection. Associated with lupus disease duration. I
      #ACR23 Abstr#1479 In N=66 patients with #SLE, 29% had high risk HPV infection. Associated with lupus disease duration. In 2nd screening ~1yr after, multiple infections occurred in 15%, about similar vs women with HIV. Call to promote HPV vaccination in SLE 💉 @RheumNow https://t.co/UGIrCwu32x
      #ACR23 Abstr#1579 More data on the role of SGLT2-i in #SLE. Data from EHR using propensity match scoring showed the use
      #ACR23 Abstr#1579 More data on the role of SGLT2-i in #SLE. Data from EHR using propensity match scoring showed the use of SGLT2-i vs DPP4-i (for nonSLE indication) was associated with reduced risk of MACE (HR:0.69)and poor renal outcomes inc. ESRD (HR:0.71) @RheumNow https://t.co/7k0o3m18AN
      In their cohort, Dr. Jorge reports that SLE pts who used SGLT2i had⬇️risk of MACE(HR 0.69 [95% CI 0.48-0.99]) &
      1 year ago
      In their cohort, Dr. Jorge reports that SLE pts who used SGLT2i had⬇️risk of MACE(HR 0.69 [95% CI 0.48-0.99]) & renal progression(HR 0.71 [95% CI 0.51-0.98]) vs DPP4 use Risk of MACE also⬇️in LN subgrp 🧐💊A potential role of SGLT2i for SLE/LN? #ACR23 ABST1579 @RheumNow #ACRbest https://t.co/Dod8DqRvLo
      #ACR23 @RheumNow
      SGLT2 inhibitors help CV & renal outcomes, but SLE pts excluded @AprilJorgeMD
      ComparedSGLT2 to DPP4
      1 year ago
      #ACR23 @RheumNow SGLT2 inhibitors help CV & renal outcomes, but SLE pts excluded @AprilJorgeMD ComparedSGLT2 to DPP4 inhibs, real world observation emulation study in SLE pts with T2DM Lower incidence of MACE & renal progression Subgroup w LN - risk reduction 10.2 MACE/100 py https://t.co/JpJ0yWNQBe
      Excellent start to Plenary II
      Should we borrow SGLT2i and DPP4i use from endocrine?
      SLE pts who initiated SGLT2 or DPP4:
      1 year ago
      Excellent start to Plenary II Should we borrow SGLT2i and DPP4i use from endocrine? SLE pts who initiated SGLT2 or DPP4: lower risk of MACE and renal progression @RheumNow #ACR23 Abs#1579 https://t.co/RsaWuetyft
      Glucocorticoids-free zone in SLE?

      For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE
      1 year ago
      Glucocorticoids-free zone in SLE? For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy. #ACR23 https://t.co/sfRhNj6OpZ https://t.co/k6VoG5lKO7
      Patients with autoimmnue diseases have a high maternal and fetal complication rate!
      Abst 1003 #ACR23 @RheumNow https://t
      Patients with autoimmnue diseases have a high maternal and fetal complication rate! Abst 1003 #ACR23 @RheumNow https://t.co/pnvvBUN2JG
      Pt w/ refractory SCLE, wants to get pregnant. Dr. Petri's approach is: counsel patient and review meds (e.g PPI's can in
      1 year ago
      Pt w/ refractory SCLE, wants to get pregnant. Dr. Petri's approach is: counsel patient and review meds (e.g PPI's can induce SCLE). She also asks: Where's your hat and sunblock? Get HCQ blood levels b/f starting anifrolumab or belimumab #ACR23 @rheumnow #MeetExpert
      Difficult SLE skin dse?
      Dr. Mosca reminds us to engage pts in the treatment process including adherence to preventive me
      1 year ago
      Difficult SLE skin dse? Dr. Mosca reminds us to engage pts in the treatment process including adherence to preventive measures & lifestyle mods (sun protection, smoking) Other considerations: + antimalarials early use of newer tx? - Anifrolumab #ACR23 @RheumNow https://t.co/kz8YfcBB2d